Rossi Residencial S/A ADS (RSRZY) Financials Nov 11, 2014,
Rossi Residencial S/A ADS (RSRZY) Financials Nov 11, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Rossi Residencial S/A ADS
Fiscal year is January-December. All values BRL millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 1.57B 2.5B 3.07B 2.01B 2.13B
Cost of Goods Sold (COGS) incl. D&A 1.13B 1.73B 2.16B 1.57B 1.73B
COGS excluding D&A 1.11B 1.71B 2.13B 1.55B 1.71B
Depreciation & Amortization Expense 22.18M 19.73M 29.41M 27.3M 19.41M
Depreciation 21.16M 18.16M 26.55M 24.71M 17.14M
Amortization of Intangibles 1.02M 1.57M 2.86M 2.59M 2.26M
Gross Income 439.4M 765.19M 914.81M 433.26M 398.47M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 226.85M 424.42M 537.83M 435.45M 350.64M
Research & Development 0 0 0 0 0
Other SG&A 226.85M 424.42M 537.83M 435.45M 350.64M
Other Operating Expense 24.64M 15.27M 5.92M 67.6M 19.28M
Unusual Expense (19.89M) (19.97M) (11.94M) 40.57M 38.08M
EBIT after Unusual Expense 19.89M 19.97M 11.94M (40.57M) (38.08M)
Non Operating Income/Expense 8.81M (32.46M) (85.05M) (72.28M) 22.81M
Non-Operating Interest Income 29.58M 109.23M 140.76M 96.64M 116.71M
Equity in Affiliates (Pretax) 0 0 0 - -
Interest Expense 5.62M 1.91M 10.62M 126.13M 129.14M
Gross Interest Expense 5.62M 1.91M 10.62M 126.13M 129.14M
Interest Capitalized 0 - 0 0 0
Pretax Income 240.58M 420.33M 428.08M (212.13M) 844,000
Income Tax 37.02M 70.56M 88.35M 56.78M 49.33M
Income Tax - Current Domestic 13.72M 25.3M 49.28M 44.2M 39.05M
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 23.3M 45.27M 39.07M 12.57M 10.28M
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 85.19M 109.04M
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 203.56M 349.77M 339.73M (183.71M) 60.56M
Minority Interest Expense 0 0 0 22M 19.5M
Net Income 203.56M 349.77M 339.73M (205.72M) 41.06M
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 203.56M 349.77M 339.73M (205.72M) 41.06M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 203.56M 349.77M 339.73M (205.72M) 41.06M
EPS (Basic) 0.95 1.29 1.25 (0.74) 0.10
Basic Shares Outstanding 213.91M 271.93M 272.22M 276.42M 418.73M
EPS (Diluted) 0.95 1.28 1.23 (0.74) 0.10
Diluted Shares Outstanding 214.09M 274.06M 275.2M 276.42M 422.83M
EBITDA 210.09M 345.23M 400.46M (42.49M) 47.95M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
Riding the Waves of Reform in China The winds of change are blowing through China's capital markets, and Guosen Securities is putting a stake in the ground with bold priorities for the 15th Five-Year Plan. As far as I'm concerned, the headlines here are thick with implications for anyone eyeing a piece of China's economic pie from 2026–2030. The Pillars of Stability and...
Continue Reading
CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...
Continue Reading
Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...
Continue Reading
Study Points to Ambient AI's Promise in Oncology Some days, the world of cancer care is a real beast to tackle. But today, we've got a glimpse into how technology, and specifically ambient AI, might just help slay some of the burdens that these healthcare warriors face daily. The Florida Cancer Specialists & Research Institute (FCS) joined hands to dive into how this tech...
Continue Reading
Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...
Continue Reading
Zinzino's Strategic Play in Europe's Wellness Market There's a new player on the European wellness block, and it's Zinzino's latest concoction of fermented botanical supplements. This isn't just your run-of-the-mill vitamin shop stock; we're talking about a lineup crafted for distinct parts of the day, reflecting an evolving consumer trend. People are looking for tailored...
Continue Reading
Making Sense of the HCLTech and Rapidus Collaboration When you're talking about the world of semiconductors, no two words get tossed around more than innovation and speed. Now, with the recent partnership between HCLTech and Rapidus, those words are bound to echo from India to Japan and beyond. We have HCLTech, a stalwart of global technology, teaming up with Rapidus, a...
Continue Reading
Running Innovation Gets a Boost in Ann Arbor On a crisp fall day up in Ann Arbor, ASICS and the University of Michigan have decided it's high time to shake up the world of running product R&D. These two powerhouses just launched the ASICSx Michigan Sport Innovation Center (AMSI), an academic-industry research lab. It's like they're mixing college smarts with business...
Continue Reading
Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...
Continue Reading
Top 5 Most Recently Viewed Articles
TuHURA Biosciences Moves Forward with Phase 3 Trial TuHURA Biosciences, Inc. (NASDAQ: HURA) is making substantial strides in the field of cancer immunotherapy. The company is geared up to launch its Phase 3 accelerated approval trial of IFx-2.0, a promising adjunctive therapy in combination with Keytruda (pembrolizumab), targeting advanced and metastatic Merkel cell...
Continue Reading
Introduction to the Class Action Lawsuit In recent news, numerous investors in Fiserv, Inc. are being alerted to an important opportunity. A class action lawsuit has been initiated targeting Fiserv, a prominent figure in the financial services tech sector. This situation arises from allegations of significant financial losses endured by shareholders due to the Company's...
Continue Reading
Understanding Humana's Short Interest Trends Recently, Humana Inc (NYSE: HUM) has reported a notable decline in its short percent of float, decreasing by 6.3% since the previous report. As of now, the company has approximately 4.30 million shares sold short, which constitutes about 3.57% of the total shares available for trading. Based on the current trading volumes, it...
Continue Reading
AI-Driven Restaurant Opening at Walmart Supercenter In an exciting development for the dining industry, Richtech Robotics Inc. (NASDAQ: RR), a leader in AI-driven service robots, has joined forces with Ghost Kitchens America to unveil their latest One Kitchen restaurant. This location, situated within a Walmart Supercenter, is marking a significant milestone as it becomes...
Continue Reading
Your Guide to MySmile Teeth Whitening Products Achieving a whiter, brighter smile is easier than ever with MySmile's effective teeth whitening solutions. MySmile offers a range of products tailored to fit different lifestyles; whether you're interested in an all-in-one kit, convenient whitening strips, or one-step solutions, the right product is just a choice away. Let's...
Continue Reading